Proven Radiotracer Catches Rare Aggressive Kidney Cancer That CT Scans Miss

A rare and devastating kidney cancer that strikes mostly adolescents and young adults may finally have a powerful new ally in the imaging suite. Renal medullary carcinoma, an unusually aggressive form of non-clear cell renal cell carcinoma, has long posed a daunting challenge for clinicians because it tends to spread silently and rapidly, often revealing itself only after the disease has already reached an advanced stage. Now, a retrospective study from The University of Texas MD Anderson Cancer Center suggests that a well-established nuclear medicine workhorse, the radiotracer fluorine-18 fluorodeoxyglucose, known universally as 18F-FDG, may be far more effective at mapping this cancer than conventional anatomical imaging alone. The findings, published in the September issue of The Journal of Nuclear Medicine, could reshape how patients with this rare malignancy are staged and treated.

The numbers reported by the research team are striking. Among 49 patients with renal medullary carcinoma who underwent 18F-FDG PET/CT scans at MD Anderson between 2016 and 2025, the radiotracer detected lesions in 98 percent of cases, or 48 of the 49 patients. Even more consequential, in 65 percent of patients the tracer revealed additional cancer lesions that were not visualized on standard anatomical imaging such as computed tomography or magnetic resonance imaging. Those extra findings were not merely academic curiosities: in 21 percent of patients with active disease, the PET/CT results directly changed the clinical management plan, steering physicians away from treatments that would have been futile or harmful and toward strategies better matched to the true extent of disease.

Renal medullary carcinoma is a disease that demands precision from the very first scan. It predominantly affects adolescents and young adults, occurs more often in males, and is strongly associated with sickle cell trait and related hemoglobinopathies, conditions in which the oxygen-carrying environment of the renal medulla appears to create conditions favorable to tumor development. At the time of diagnosis, patients frequently already present with metastatic disease, and the median overall survival is approximately 14.5 months. Against that grim backdrop, every staging decision carries enormous weight. Surgery that might offer curative potential in localized disease becomes a source of suffering and delay when the cancer has in fact spread undetected, because high-morbidity operations postpone the systemic therapies that metastatic patients urgently need.

Simone Krebs, MD, MS, a nuclear medicine physician and scientist at MD Anderson and the study’s lead author, emphasized just how much rides on getting staging right in this disease. In renal medullary carcinoma, she noted, the value of accurate staging cannot be overstated, because upstaging a patient from localized to metastatic disease spares them from noncurative, high-morbidity surgeries that would only delay the initiation of essential systemic therapy. Identifying metastatic disease, she added, may also open opportunities for more effective therapies tailored to a patient’s actual disease burden. Her comments underscore a central tension in oncology: the difference between what imaging shows and what the cancer is actually doing can determine whether a patient receives the right treatment at the right time or loses precious months to the wrong one.

The biological basis for the study’s success lies in the way renal medullary carcinoma handles glucose. 18F-FDG is a glucose analog labeled with fluorine-18; it is taken up by cells through glucose transporters and then becomes metabolically trapped, allowing positron emission tomography to visualize tissues with high glycolytic activity. Many cancers are avid for FDG, but uptake varies considerably across kidney tumor subtypes, which has historically limited the tracer’s reputation in urologic oncology. Clear cell renal cell carcinoma, the most common kidney cancer, often shows variable FDG uptake, and some renal lesions are better characterized by other tracers or by dedicated CT protocols. Renal medullary carcinoma, however, demonstrates strong and consistent FDG uptake, distinguishing it from other kidney cancers and making it an unusually suitable target for FDG PET/CT imaging.

That metabolic avidity translated into practical diagnostic power even in patients who had already begun systemic treatment. The study found that 18F-FDG PET/CT remained highly effective after therapy had been initiated, an important point because treatment can alter tumor metabolism and degrade the performance of metabolic imaging in some cancers. In renal medullary carcinoma, the tracer continued to illuminate active disease, giving oncologists a reliable way to assess how patients were responding and whether residual lesions represented viable tumor. Quantitative PET/CT metrics were evaluated alongside visual interpretation, and the researchers systematically recorded every instance in which imaging findings altered treatment, providing a structured account of the scan’s real-world impact rather than anecdotal impressions.

The clinical consequences of the additional findings were often dramatic. In one illustrative case included in the published work, a patient demonstrated intense focal FDG uptake in nodal, hepatic, soft-tissue, and osseous metastases on maximum-intensity-projection imaging. Axial FDG PET and fused PET/CT images revealed focal intense uptake in the right iliac bone, a finding without a definite correlate on the dedicated CT image. That discrepancy, a metabolically active lesion invisible on anatomical imaging, led directly to changes in the patient’s clinical management. It is precisely this pattern, PET revealing disease that CT cannot confirm, that explains how the tracer upstaged so many patients and redirected so many treatment plans in the study cohort.

For patients, the implications of these findings are potentially life-altering. A young adult with renal medullary carcinoma who appears to have localized disease on a conventional CT scan might, in fact, harbor hepatic, nodal, or bone metastases that only PET/CT can reveal. Detecting those lesions before surgery could spare the patient a major operation that would never have been curative, while simultaneously accelerating access to systemic therapy, the treatment modality most likely to extend survival in metastatic disease. Conversely, for patients whose PET/CT confirms truly limited disease, the scan provides confidence that aggressive local treatment is justified. In both directions, the additional information changes decisions, and in a cancer with a median survival measured in months, better decisions translate directly into better use of the limited time available.

The study’s authors argue that the evidence now justifies a formal change in clinical practice. Their conclusion is that the findings may support the inclusion of 18F-FDG PET/CT in upcoming guidelines regarding renal medullary carcinoma, which would enable broader clinical use beyond specialized centers like MD Anderson. Guideline inclusion matters because renal medullary carcinoma is rare enough that many treating institutions will encounter only a handful of cases, and clinicians may default to conventional staging pathways unless professional society recommendations explicitly endorse metabolic imaging. Krebs and her colleagues contend that PET/CT provides clinically meaningful information beyond conventional imaging, helping doctors better assess the extent of disease and choose the most appropriate treatment strategy, and that on a larger scale the research supports wider adoption in routine patient care.

As molecular imaging continues to expand its role in oncology, the MD Anderson study offers a compelling case study in how an old, proven tool can find new purpose in an underserved disease. 18F-FDG has been a staple of nuclear medicine for decades, yet its value in kidney cancer has been considered limited and subtype-dependent. By rigorously documenting its performance specifically in renal medullary carcinoma, a population of predominantly young patients with few good options, the researchers have turned a routine radiotracer into a potential standard of care for one of oncology’s most aggressive diagnoses. With 98 percent detection, additional lesions found in nearly two-thirds of patients, and management changes in one in five, the case for FDG PET/CT in this disease is difficult to ignore, and the coming updates to clinical guidelines may soon make this powerful scan a routine part of the fight against renal medullary carcinoma.

Subject of Research: Use of 18F-FDG PET/CT imaging for staging and treatment planning in renal medullary carcinoma

Article Title: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer

Article References: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: renal medullary carcinoma, 18F-FDG PET/CT, kidney cancer, molecular imaging, metastatic disease, staging, nuclear medicine, radiotracer, MD Anderson Cancer Center, treatment planning, non-clear cell renal cell carcinoma, Journal of Nuclear Medicine